Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2007-01-02
2007-01-02
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C530S323000, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S403000, C530S806000, C530S828000, C530S332000, C424S184100, C424S185100, C424S192100, C424S193100, C424S277100, C514S002600, C514S012200, C514S013800, C514S014800, C514S015800, C514S885000
Reexamination Certificate
active
09336091
ABSTRACT:
The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.
REFERENCES:
patent: 5965535 (1999-10-01), Chaux et al.
patent: 6043347 (2000-03-01), Gelder
patent: WO 95/04542 (1995-02-01), None
patent: WO 95/20974 (1995-08-01), None
patent: WO 97/11669 (1997-04-01), None
patent: WO 99/14326 (1999-03-01), None
Chaux et al.,J. Exp. Med., 189(5):767-777 (1999).
Sanderson et al.,Proc. Natl. Acad. Sci. USA, 92(16):7217-7221 (1995).
Spatola,Chem.and Biochem. of Amino Acids, Peptides and Proteins, 7:267-357 (1983).
Manici et al.,J. Exp. Med., 189(5):871-876 (1999).
Büeler et al.,Molecular Medicine, 2(5): 545-555 (1996).
Topalian et al.,J. Exp. Med., 183(5): 1965-1971 (1996).
Topalian, S.L.,Current Opinion in Immunol., 6: 741-745 (1994).
Boon-Falleur Thierry
Chaux Pascal
Lethe Bernard
van der Bruggen Pierre
Van Snick Jacques
Ludwig Institute for Cancer Research
Schwadron Ronald B.
Wolf Greenfield & Sacks P.C.
LandOfFree
MAGE-A1 peptides presented by HLA class II molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MAGE-A1 peptides presented by HLA class II molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAGE-A1 peptides presented by HLA class II molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745531